Cell and Gene Therapy Manufacturing Services Market is estimated to increase at a Compounded Annual Growth Rate of 22.3% CAGR over the forecast period from 2024 to 2030
The Cell and Gene Therapy Manufacturing Services Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Type (Cell Therapy, Gene Therapy), By Indication (Oncology, Cardiovascular, Orthopedic, Ophthalmology, Central Nervous System, Infectious Diseases, Others), By Application (Clinical Manufacturing, Commercial Manufacturing), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others).
An Introduction to Cell and Gene Therapy Manufacturing Services Market in 2024
Cell and gene therapy manufacturing services encompass a range of contract manufacturing solutions for the production, processing, and quality control of cell-based and gene-based therapies. In 2024, these services include process development, technology transfer, cGMP manufacturing, and regulatory support to assist biopharmaceutical companies in bringing cell and gene therapies from concept to commercialization. Cell and gene therapy manufacturing services offer specialized expertise and infrastructure for scalable production of therapeutic cells, viral vectors, and gene-modified cells for clinical trials and commercial distribution. These services adhere to stringent quality and regulatory standards to ensure product safety, efficacy, and consistency throughout the manufacturing process. With advancements in manufacturing technologies, automation, and analytical methods, cell and gene therapy manufacturing services continue to evolve, enabling the production of innovative therapies for treating a wide range of genetic, autoimmune, and degenerative diseases. As cell and gene therapies gain momentum in the biopharmaceutical industry, manufacturing services play a critical role in accelerating the translation of promising therapies into approved treatments for patients in need.
Market Trend: Increasing Demand for Personalized Medicine Solutions
In the realm of cell and gene therapy manufacturing services, a significant trend emerges in the form of increasing demand for personalized medicine solutions. With advancements in biotechnology and genomics, there's a growing understanding of individualized treatment approaches. As a result, there's a shift towards therapies tailored to patients' specific genetic makeup and medical history. This trend necessitates more flexible and adaptable manufacturing processes to accommodate the variability inherent in personalized treatments. Companies offering cell and gene therapy manufacturing services must align their capabilities with this trend to stay competitive in the market.
Market Driver: Accelerated Research and Development Activities
One of the primary drivers propelling the cell and gene therapy manufacturing services market forward is the accelerated pace of research and development activities. The continuous influx of investment, both from the public and private sectors, fuels innovation in this field. Breakthroughs in genetic engineering, gene editing technologies like CRISPR-Cas9, and advancements in cell culturing techniques contribute to the development of novel therapies. This heightened R&D activity not only expands the pipeline of potential treatments but also increases the demand for manufacturing services to bring these therapies from the lab to market efficiently.
Market Opportunity: Expansion of Outsourcing Partnerships
An emerging opportunity within the cell and gene therapy manufacturing services market lies in the expansion of outsourcing partnerships. As biopharmaceutical companies focus on their core competencies in research and clinical development, they seek specialized expertise for manufacturing. This presents an opportunity for service providers to offer comprehensive solutions, including process development, manufacturing, and analytical testing. Collaborative partnerships between biotech firms and manufacturing service providers can streamline production, mitigate risks, and accelerate time to market for innovative therapies. This trend opens avenues for companies to establish themselves as trusted partners in the rapidly evolving landscape of advanced therapeutics.
Cell and Gene Therapy Manufacturing Services Market Share Analysis: Gene Therapy Manufacturing Services is the fastest growing segment over the forecast period to 2030
Gene therapy manufacturing services represent the fastest-growing segment within the cell and gene therapy manufacturing market. This growth can be attributed to several key factors. Firstly, the increasing number of gene therapy clinical trials across a wide range of therapeutic areas, including oncology, ophthalmology, and central nervous system disorders, is driving demand for manufacturing services to produce viral and non-viral vectors used in gene delivery. Secondly, advancements in gene editing technologies, such as CRISPR-Cas9, have expanded the potential applications of gene therapy, leading to a surge in research and development activities requiring manufacturing support. Additionally, the recent regulatory approvals of gene therapy products and the growing investment in this field by pharmaceutical and biotechnology companies have further propelled the demand for manufacturing services, both for clinical and commercial purposes. With the continuous evolution of gene therapy approaches and the increasing emphasis on personalized medicine, the demand for manufacturing services is expected to remain robust, positioning gene therapy manufacturing as the fastest-growing segment in the cell and gene therapy manufacturing market.
Cell and Gene Therapy Manufacturing Services Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossABL Inc, Andelyn Biosciences LLC, Anemocyte Srl, BioCentriq LLC, Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, ElevateBio Holdings Inc, FinVector Oy, Forge Biologics Inc, FUJIFILM Holdings Corp, Genezen Laboratories Ltd, JRS Pharma LP, Lonza Group Ltd, Merck KGaA, Nikon Corp, Oxford Biomedica plc, Porton Advanced Solutions Ltd, Resilience Corp, RoslinCT , Takara Bio Inc, The Discovery Labs LLC, Thermo Fisher Scientific Inc, Vibalogics GmbH, WuXi AppTec Co. Ltd
Cell and Gene Therapy Manufacturing Services Market Segmentation
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Cell and Gene Therapy Manufacturing Services Market Companies
ABL Inc
Andelyn Biosciences LLC
Anemocyte Srl
BioCentriq LLC
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
ElevateBio Holdings Inc
FinVector Oy
Forge Biologics Inc
FUJIFILM Holdings Corp
Genezen Laboratories Ltd
JRS Pharma LP
Lonza Group Ltd
Merck KGaA
Nikon Corp
Oxford Biomedica plc
Porton Advanced Solutions Ltd
Resilience Corp
RoslinCT
Takara Bio Inc
The Discovery Labs LLC
Thermo Fisher Scientific Inc
Vibalogics GmbH
WuXi AppTec Co. Ltd
Reasons to Buy the Cell and Gene Therapy Manufacturing Services Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cell and Gene Therapy Manufacturing Services Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cell and Gene Therapy Manufacturing Services Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Cell and Gene Therapy Manufacturing Services Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Cell and Gene Therapy Manufacturing Services Market Size Outlook, $ Million, 2021 to 2030
3.2 Cell and Gene Therapy Manufacturing Services Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cell and Gene Therapy Manufacturing Services Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cell and Gene Therapy Manufacturing Services Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cell and Gene Therapy Manufacturing Services Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Cell and Gene Therapy Manufacturing Services Industry
4.2 Key Market Trends in Cell and Gene Therapy Manufacturing Services Industry
4.3 Potential Opportunities in Cell and Gene Therapy Manufacturing Services Industry
4.4 Key Challenges in Cell and Gene Therapy Manufacturing Services Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cell and Gene Therapy Manufacturing Services Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Cell and Gene Therapy Manufacturing Services Market Outlook by Segments
7.1 Cell and Gene Therapy Manufacturing Services Market Outlook by Segments, $ Million, 2021- 2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
8 North America Cell and Gene Therapy Manufacturing Services Market Analysis and Outlook To 2030
8.1 Introduction to North America Cell and Gene Therapy Manufacturing Services Markets in 2024
8.2 North America Cell and Gene Therapy Manufacturing Services Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cell and Gene Therapy Manufacturing Services Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
9 Europe Cell and Gene Therapy Manufacturing Services Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cell and Gene Therapy Manufacturing Services Markets in 2024
9.2 Europe Cell and Gene Therapy Manufacturing Services Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cell and Gene Therapy Manufacturing Services Market Size Outlook by Segments, 2021-2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
10 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cell and Gene Therapy Manufacturing Services Markets in 2024
10.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cell and Gene Therapy Manufacturing Services Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
11 South America Cell and Gene Therapy Manufacturing Services Market Analysis and Outlook To 2030
11.1 Introduction to South America Cell and Gene Therapy Manufacturing Services Markets in 2024
11.2 South America Cell and Gene Therapy Manufacturing Services Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cell and Gene Therapy Manufacturing Services Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
12 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cell and Gene Therapy Manufacturing Services Markets in 2024
12.2 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cell and Gene Therapy Manufacturing Services Market size Outlook by Segments, 2021-2030
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ABL Inc
Andelyn Biosciences LLC
Anemocyte Srl
BioCentriq LLC
Catalent Inc
Cell and Gene Therapy Catapult
Charles River Laboratories International Inc
ElevateBio Holdings Inc
FinVector Oy
Forge Biologics Inc
FUJIFILM Holdings Corp
Genezen Laboratories Ltd
JRS Pharma LP
Lonza Group Ltd
Merck KGaA
Nikon Corp
Oxford Biomedica plc
Porton Advanced Solutions Ltd
Resilience Corp
RoslinCT
Takara Bio Inc
The Discovery Labs LLC
Thermo Fisher Scientific Inc
Vibalogics GmbH
WuXi AppTec Co. Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Type
Cell Therapy
-Allogeneic
-Autologous
-Viral Vector
Gene Therapy
-Viral Vector
-Non-viral Vector
By Indication
Oncology
Cardiovascular
Orthopedic
Ophthalmology
Central Nervous System
Infectious Diseases
Others
By Application
Clinical Manufacturing
Commercial Manufacturing
By End-User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
